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Effect of statins on atrial fibrillation: collaborative meta-
analysis of published and unpublished evidence from
randomised controlled trials
Kazem Rahimi, James Martin senior fellow in essential healthcare,1 cardiologist,2 Jonathan Emberson,
statistician,3 Paul McGale, statistician,3 William Majoni, nephrologist,4 Amal Merhi, statistician,3 Folkert W
Asselbergs, cardiologist,5,6,7 Vera Krane, nephrologist,8 Peter W Macfarlane (on behalf of the PROSPER
Executive), emeritus professor9
ABSTRACT
Objective To examine whether statins can reduce the risk
of atrial fibrillation.
DesignMeta-analysis of published and unpublished
results from larger scale statin trials, with comparison of
the findings against the published results from smaller
scale or shorter duration studies.
Data sourcesMedline, Embase, and Cochrane’s CENTRAL
up to October 2010. Unpublished data from longer term
trials were obtained through contact with investigators.
Study selection Randomised controlled trials comparing
statin with no statin or comparing high dose versus
standard dose statin; all longer term trials had at least
100 participants and at least six months’ follow-up.
Results In published data from 13 short term trials (4414
randomised patients, 659 events), statin treatment
seemed to reduce the odds of an episode of atrial
fibrillation by 39% (odds ratio 0.61, 95% confidence
interval 0.51 to 0.74; P<0.001), but there was significant
heterogeneity (P<0.001) between the trials. In contrast,
among 22 longer term and mostly larger trials of statin
versus control (105791 randomised patients, 2535
events), statin treatment was not associated with a
significant reduction in atrial fibrillation (0.95, 0.88 to
1.03; P=0.24) (P<0.001 for test of difference between the
two sets of trials). Seven longer term trials of more
intensive versus standard statin regimens (28964
randomised patients and 1419 events) also showed no
evidence of a reduction in the risk of atrial fibrillation
(1.00, 0.90 to 1.12; P=0.99).
Conclusions The suggested beneficial effect of statins on
atrial fibrillation from published shorter term studies is
not supported by a comprehensive review of published
and unpublished evidence from larger scale trials.
INTRODUCTION
Atrial fibrillation is the most common form of cardiac
arrhythmia in clinical practice and its prevalence
increases with age.1 In England and Wales, for
instance, it has been estimated that about 0.7% of
men and 0.4% of women aged 45-54 are affected, but
these proportions rise to about 9% and 7%, respec-
tively, by age 75-84.2 Moreover, because of increases
in life expectancy in most countries, as well as conse-
quent increases in the prevalence of heart failure, the
overall global burden from atrial fibrillation is likely to
increase substantially in the coming decades.Although
not acutely life threatening, the haemodynamic com-
promise and increased risk of stroke associated with
chronic atrial fibrillation13 can cause severe morbidity
and mortality (especially among older people4 and
those with heart failure5). Atrial fibrillation is therefore
responsible formuch impairment of quality of life6 and
causes a substantial burden to health services,7 but
there is little reliable evidence from large scale rando-
mised controlled trials about how to prevent it.8
Recently, there has been some evidence for the pro-
tective role of statins in reducing the risk of atrial fibril-
lation. In particular, one meta-analysis identified six
trials involving 386 events (165 statin v 221 control)
and suggested that statins could reduce the risk of atrial
fibrillation by 61% (95% confidence interval 15% to
82%).9 A second meta-analysis comprising six trials
(five of which were included in the first meta-analysis),
however, yielded a more modest (and non-significant)
point estimate of 24% (−5% to 45%; 177 statin v 220
control).10 In both meta-analyses, the findings from
the included trials were highly heterogeneous, and the
highly selected populations of patients in these trials
raised questions about the applicability of the findings
to much larger populations at risk of atrial fibrillation.
Thus, many experts have called for more research,
acknowledging that the conduct of large scale rando-
mised statin trials with atrial fibrillation as the primary
outcome could pose numerous practical, financial, and
ethical challenges.8 In the absence of such trials, the
wealth of available information from many large scale
randomised controlled trials that have collected but not
necessarily published information on atrial fibrillation
offers an opportunity to test the hypothesis generated
by the previous meta-analyses.
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We investigatedwhether longer term treatment with
statins can reduce the risk of atrial fibrillation in a wide
range of people by performing a meta-analysis of pub-
lished and unpublished findings from all larger scale
statin trials, many of which were conducted in popula-
tions at risk of atrial fibrillation because of underlying
cardiac disease.
METHODS
Search strategy for identification of relevant studies
WesearchedMedline (January 1966 toOctober 2010),
Embase (January 1985 to 2010 week 40), and the
Cochrane Central Register of Controlled Trials
(Cochrane Library, issue 4, October 2010) for articles
with a subject term “hydroxymethylglutaryl-coen-
zyme A reductase inhibitor” or any of the following
terms: “hydroxymethylglutaryl-co A reductase inhibi-
tor”, “statin”, “fluvastatin”, “pravastatin”, “lovastatin”,
“simvastatin”, “atorvastatin”, or “rosuvastatin”. The
search was limited to randomised controlled trials
with no language restrictions.
Review methods and selection criteria
Two reviewers independently screened all titles and
abstracts for randomised controlled trials with either
a parallel or factorial design, at least one comparison
of a statin versus a control regimen or a more versus
less intensive statin regimen, and a total of 100 ormore
randomised participants followed up for at least six
months. There were no restrictions on participants’
characteristics or study outcomes. We also hand
searched the reference lists of these studies to ensure
that we did not miss other relevant articles, such as
meta-analyses of statin trials or other types of articles
related to statins and cardiac arrhythmias. After
removing duplicate reports, we examined full text arti-
cles of all remaining reports (fig 1).
Data abstraction
For each trial, we recorded the study’s or investigator’s
name; mean duration of follow-up; year of publication
of the primary findings; randomised treatments; sum-
mary information about the studied population (num-
ber of participants, mean age, number of men, and
prevalence of myocardial infarction or heart failure at
randomisation); and the primary outcome of the study.
The number of patients with at least one reported epi-
sode of atrial fibrillation was recorded. In trials where
information on atrial fibrillation had not previously
been published, we asked the investigators to abstract
the relevant numbers from their routine records of
adverse events. Non-responders were sent a reminder
after about three weeks and, when possible, were then
contacted by telephone.
Updated search for short term trials
The two previous meta-analyses (both published in
2008)910 included statin trials that had previously pub-
lished results on atrial fibrillation. Because these meta-
analyses were themselves a fewmonths old by the time
our search for the longer term trials began, we also
performed an updated search for any smaller pub-
lished statin trials that had reportedon atrial fibrillation
and were published since the data search in the pre-
viousmeta-analyses up toOctober 2010. Unpublished
data from trials that did not have at least 100 partici-
pants randomised and at least six months’ follow-up
were not sought.
Assessment of risk of bias
To identify potential sources of bias in the reported
events of atrial fibrillation (according to the Cochrane
Statistical Methods Group and the Cochrane Bias
Methods Group) we considered sequence generation,
concealment of allocation sequence, blinding, incom-
plete outcome data, selective outcome reporting, and
any other potential sources of bias. Risk of bias at the
individual trial level and across the two sets of trialswas
categorised into low, unclear, and high.
Statistical analysis
Our primary hypothesis was to test whether longer
term treatment with statins reduces the risk of atrial
fibrillation. We therefore considered the shorter term
trials included in the two previous meta-analyses (as
well as any further short term trials) separately from
the longer term statin trials. Although the previous
two meta-analyses had no restriction on the size or
duration of the trials included, none of the trials
included in those meta-analyses (or the six found sub-
sequently) had a planned treatment duration of more
than six months and a sample size of 100 or more par-
ticipants, so our electronic searches identified a non-
overlapping group of longer term trials. Our primary
analyses were restricted to trials of statin versus control
(that is, placebo or usual care). As the anti-inflamma-
tory effect of statins—one of the key mechanisms for
their potential anti-arrhythmic effects11 12—might be
more pronounced in high dose statin treatment,13 we
also carried out secondary analyses based on the trials
that had compared a more intensive versus a standard
statin regimen.
For every trial, we calculated the “observed minus
expected” statistic (O−E) and its variance (V) from
the number of patients who developed atrial fibrilla-
tion and the total number of patients in each treatment
group, using standard formulas for 2×2 contingency
tables. These (O−E) values, one from every trial,
were summed to produce a grand total (G), with var-
iance (V) equal to the sum of their separate variances.
The value exp(G/V) is Peto’s “one step” estimate of the
odds ratio, and its continuity corrected 95%confidence
interval is given by exp(G/V ± (0.5/V + 1.96/√V).14
Odds ratios are given with 95% confidence intervals
for the overall results and with 99% confidence inter-
vals (replacing 1.96 in the formula above by 2.576) for
individual trial results and subgroup results. We
assessed the heterogeneity between the different
hypothesis testing trials by calculating S−G2/V,
where S is the sum of (O−E)2/V for each trial, and test-
ing this statistic against a χ2 distribution with degrees of
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freedom equal to one less than the number of trials. In
forest plots, trials are shown in order of the amount of
statistical information they contribute to the overall
result. The summary odds ratios from the two sets of
trials were compared with a standard χ2 test (on 1
degree of freedom).
To assess the potential for a differential effect of sta-
tins on atrial fibrillation in different clinical settings, we
performed two separate subgroup analyses among the
statin versus control trials. One assessed the effect of
statins separately among trials in which reports were
known to have beenof first diagnosed episodes of atrial
fibrillation, trials in which reports were known to have
been recurrences of previously diagnosed paroxysmal
atrial fibrillation, and trials in which it was unknown
whether reports were first diagnosed or recurrent
events. The other subgroup analysis tested whether
the effect of statins might differ in people at different
underlying risk of atrial fibrillation by looking at the
treatment effects separately for three groups of trials,
according to the predominant type of participants:
patients without previous coronary heart disease,
patients with previous coronary heart disease, and
patients with known heart failure or end stage renal
disease. (Trials that largely included patients with
heart failure or end stage renal diseasewere considered
together because of the large clinical overlap between
these two groups of patients: heart failure is highly
prevalent in people with kidney failure,15 and both
groups are at increased risk of atrial fibrillation.16 17)
Statistical analyses were done with R version 2.2.1.18
All statistical testswere two sided, and all analyseswere
done on an intention to treat basis.
RESULTS
Shorter term trials
The two previous meta-analyses9 10 contained data on
seven trials,19-25 yielding a total of 3608 randomised
patients and about 1050 person years of follow-up (0.
3 years per patient). In addition, we identified six
further statin trials that had published data on atrial
fibrillation (but were not eligible to be considered as
long term trials) (table 1). 26-31 With the exception of
one trial, all shorter term trials were restricted to
patients in whom cardiac surgery or electrical cardio-
version was planned.Most short term trials used sensi-
tive event capturing methods and included short
episodes of atrial fibrillation on continuous electrocar-
diographic monitoring as relevant study outcomes
regardless of presence or absence of symptoms. The
potential risk of bias was judged to be high in four of
the trials and unclear in a further four.
In the 13 shorter term trials combined (4414
patients, 1129 person years of follow-up), a report of
atrial fibrillation on at least one occasion during fol-
low-up occurred among 659 patients (fig 2). Within
these trials, treatment with statins was associated with
a reduced odds of atrial fibrillation, by 39% (275
(12.5%) in the statin group versus 384 (17.4%) in the
control group (odds ratio 0.61, 95% confidence inter-
val 0.51 to 0.74; P<0.001; fig 2). There was significant
heterogeneity between the trials (χ2=43.4, df=12,
P<0.001), caused in part by one study with an extreme
relative reduction in the odds of atrial fibrillation (14
(35%) v 36 (90%); continuity corrected χ2=23.2, df=1,
P<0.001). 21 Even within the 12 other trials, however,
we observed a highly significant 34% reduction in the
odds of atrial fibrillation (261 v 348; 0.66, 0.55 to 0.81),
albeit still with significant heterogeneity between these
12 trials (χ2=26.9, df=11, P<0.001). In the largest trial,
therewas no significant reduction in risk (93 (6.0%) v96
(6.2%) events; P=0.86). 20 Exclusion of the four trials in
which the potential for bias was thought to be high had
little effect on the estimated odds ratio in the remaining
nine trials (249 v 345; 0.62, 0.51 to 0.76).
Longer term trials
Out of 4033 abstracts reviewed, we retrieved 218
papers describing 101 longer term trials for further
examination, 79 of which met the inclusion criteria
(fig 1). Of these 79 trials, atrial fibrillation was not
recorded in 23 (18 000 patients and 68 000 person
years) and data were not readily available to the inves-
tigators in 18 (21 000 patients, 83 000 person years). Of
the remaining 38 trials, all except ninewere included in
the currentmeta-analysis (therewas no response to our
request for data for seven trials (4900 patients, 5900
person years), and information was not available in
two trials because of restrictions on sharing
Abstracts reviewed after removal of duplicate reports (n=4033)
Potentially relevant reports on 101 studies retrieved for full text review (n=218)
Studies where availability of information was confirmed or could not be excluded (n=38)
Potentially eligible studies considered for inclusion and
investigators contacted for relevant missing information (n=79)
Reports excluded based on title and abstract (n=3815):
  Not a randomised trial
  Crossover design
  Duration <6 months
  <100 participants
  Not statin v control or more v less intensive statin regimen
  Non-human studies
Studies excluded because eligibility criteria were not met (n=22):
  Duration <6 months (n=14)
  <100 participants (n=3)
  Ongoing trials (n=3)
  Not statin v control or more v less intensive statin regimen (n=2)
Studies comprising 39 779 participants and about 151 000 person years excluded (n=41):
  No events recorded (18 498 participants, about 68 000 person years) (n=23)
  Information not accessible to investigators (21 281 participants, about 83 000 person
    years) (n=18)
Studies comprising 14 674 participants and about 43 000 person years excluded (n=9):
  No response to data request (4932 participants, about 5900 person years) (n=7)
  Unable to provide data (9742 participants, about 37 000 person years) (n=2)
Studies comprising 134 755 participants and about 519 000 person years included (n=29):
  Studies comparing statin v no statin (105 791 participants, about 410 000 person years and 2535
    events) (n=22)
  Studies comparing more v less intensive statin regimen (28 964 participants, about 110 000
    person years and 1419 events) (n=7)
Fig 1 | Search retrieval process for studies of statins
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unpublished data (10 000 patients, 37 000 person
years)). Of the 29 included trials, 13 32-58 six provided
data on atrial fibrillation in the published
reports32 48 49 54 57 and investigators in the remaining
23 provided the data on request. There were no
obvious systematic differences between the trials that
were and were not included.
Tables 2 and 3 show the characteristics of the 29
longer term trials. Twenty two trials (including
105 791 randomised participants and 410 000 person
years of follow-up) compared a statin with a control
regimen and seven trials (including 28 964 randomised
participants and 110 000 person years of follow-up)
compared a more intensive with a standard statin regi-
men. Event informationwasmostly based on routinely
collected data on adverse events, with the exception of
six trials that used periodic electrocardiography,
including at the end of the study,32 35 38 41 42 48 and one
study that used a prespecified definition of atrial fibril-
lation based on pacemaker interrogation.49 Nine trials
confirmed reports of atrial fibrillation.32 35 38 41 42 48 49 54
Of these, seven recorded baseline information about
the presence or absence of atrial fibrillation (either as
a clinical history or onECGevidence) and hence could
confirm that the numbers provided were first diag-
nosed occurrences of atrial fibrillation32 35 38 41 42 48 49 or
definite recurrences of known paroxysmal atrial
fibrillation. 48 In all other trials, such information was
not available, so a subset of the reported events could
represent symptomatic recurrences of previously diag-
nosed atrial fibrillation. The potential risk of bias in the
longer term trials was judged to be low in all but one
trial. 49 Exclusion of this trial hadno effect on the results
(as it contributed just 13 events).
The primary analyses were restricted to the 22
longer term trials that compared a statin with a control
regimen. In these trials, 2535 patients experienced an
episode of atrial fibrillation. Statin treatment did not
significantly reduce the risk of atrial fibrillation (1240
(2.3%) statin v 1295 (2.5%) control, odds ratio 0.95,
0.88 to 1.03; P=0.24), and there was no evidence that
the effect of statin treatment varied within these trials
(heterogeneity χ2=21.9, df=21, P=0.40; fig 2). An
uncorrected test of the combined results from the 13
short term and 22 long term trials would not be statis-
tically appropriate because seven out of the 13 shorter
term trials generated the hypothesis being tested in the
longer term trials (which could lead to a point estimate,
confidence interval, and P value that are appreciably
biased). 59 60 Consequently, the suggestion of a small
reduction in risk when all 35 trials are considered
together (0.89, 0.82 to 0.95; P=0.002) should be inter-
preted with caution.
In the seven longer term trials that examined amore
intensive compared with a standard statin regimen,
there was no evidence that higher dose statin reduced
Table 1 | Summary of characteristics of short term trials on effect of statins
Study
Mean
follow-up
(years)
Country /
region
Intervention/
control
Main inclusion
criteria Event capturing methods
No in
intervention/
control
Mean
age
(years)
Male
(%)
Previous
MI (%)
Potential
risk of
bias
Tveit et al, 200419 0.12 Norway Pravastatin
40 mg/no treatment
Cardioversion Serial ECG recording 51/51 68 87 — Unclear
MIRACL, 200420 0.31 Multinational Atorvastatin
80 mg/placebo
Acute coronary
syndrome
Serial ECG recording 1538/1548 65 65 25 Low
Dernellis et al,
200521
0.42 Greece Atorvastatin
20-40 mg/placebo
Paroxysmal
atrial fibrillation
48 hour ambulatory ECG once
during follow-up
40/40 52* 65 — Unclear
ARMYDA-3,
200622
0.08 Italy Atorvastatin
40 mg/placebo
Planned cardiac
surgery
Continuous ECGmonitoring for
6 days followed by daily ECG
recording until discharge
101/99 66 74 43 Low
Chello et al,
200623
0.06 Italy Atorvastatin
20 mg/placebo
Planned CABG Postoperative monitoring 20/20 65 78 — Unclear
Ozaydin et al,
200624
0.25 Turkey Atorvastatin
10 mg/no treatment
Cardioversion 24 hour ambulatory ECG
monitoring at 1 and 3 month
follow-up
24/24 62 60 0 High
Garcia-Fernandez
et al, 200625
0.08 Spain Atorvastatin
80 mg/no treatment
Cardioversion ECG recording at 3 months or
clinical event
27/25 –— — — High
Songetal,200826 0.02 Korea Atorvastatin
20 mg/no treatment
Planned CABG Continuous ECG monitoring
until discharge
62/62 63 40 7 High
Mannacio et al,
200827
0.05 Italy Rosuvastatin
20 mg/placebo
Planned CABG Postoperative monitoring 100/100 73 60 23 Low
Tamayo et al,
200828
0.39 Spain Simvastatin
20 mg/no treatment
Planned CABG Postoperative monitoring 22/22 68 65 0 High
Almroth et al,
200929
0.13 Sweden Atorvastatin
80 mg/placebo
Cardioversion Serial ECG recording 118/116 65 76 — Low
Xia et al, 200930 0.25 China Rosuvastatin
20 mg/no treatment
Cardioversion 24 hour ambulatory ECG
monitoring
32/32 61 98 — Unclear
Ji et al, 200931 0.04 China Atorvastatin
20 mg/placebo
Planned CABG Continuous ECG monitoring
7 days followed by daily ECG
recording until discharge
71/69 66 49 — Low
MI=myocardial infarction; ECG=electrocardiography; CABG=coronary artery bypass graft surgery.
*Median.
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the risk of atrial fibrillation compared with standard
dose statin (710 (4.9%) v 709 (4.9%), respectively;
1.00, 0.90 to 1.12; P=0.99; fig 3).
In subgroup analyses, there was no evidence that
statin treatment was effective in preventing first diag-
nosed atrial fibrillation (574 (4.1%) statin v 597 (4.3%)
control; fig 4), and there was no evidence that the effect
of statin treatment differed in trials that studied mainly
people with no previous coronary heart disease,
mainly people with previous coronary heart disease,
or mainly people with heart failure or advanced
chronic kidney disease (χ2=5.05, df=2, P=0.08 for het-
erogeneity between these three categories; fig 4). Most
of the longer term trials of statin versus control
reported events that were not adjudicated, but when
the analyses were restricted to those seven trials that
had independently confirmed the events, 32 35 38 41 42 48 49
there was also no significant reduction in the risk of
atrial fibrillation (676 (4.7%) statin v 711 (5.0%) control;
0.94, 0.84 to 1.05; P=0.29).
Shorter term trials (published only)
  Tamayo et al28
  Chello et al23
  Ozaydin et al24
  Xia et al30
  Garcia-Fernandez et al25
  Dernellis et al21
  Song et al26
  Tveit et al19
  Ji et al31
  Mannacio et al27
  ARMYDA-322 
  Almroth et al29
  MIRACL20
Subtotal: 13 trials, P<0.001
Test for heterogeneity: χ2=43.4, df=12, P<0.001
Longer term trials (published and unpublished)
  PCAB43
  METEOR51
  ASCOT-LLA39
  LEADe53
  Sola et al47
  ATAHEB49
  Vrtovec et al50
  PREVEND IT42
  GISSI-P34
  WOSCOPS32
  LIPS37
  AFCAPS/TexCAPS33
  CARDS41 
  ALLIANCE40
  MEGA45
  ASPEN46
  4D44
  ALLHAT-LLT35
  JUPITER52
  HPS36
  GISSI-HF48
  PROSPER38
Subtotal: 22 trials, P=0.24
Test for heterogeneity: χ2=22.1, df=21, P=0.40
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0.10 (0.03 to 0.35)
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1.00 (0.24 to 4.19)
1.33 (0.47 to 3.78)
0.58 (0.22 to 1.51)
1.43 (0.59 to 3.48)
0.77 (0.34 to 1.72)
0.83 (0.41 to 1.69)
0.94 (0.46 to 1.91)
1.12 (0.58 to 2.15)
0.83 (0.46 to 1.52)
0.77 (0.42 to 1.39)
1.02 (0.67 to 1.54)
0.85 (0.63 to 1.14)
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0.85 (0.66 to 1.08)
1.09 (0.86 to 1.38)
0.95 (0.88 to 1.03)
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2 (10.0)
3 (12.5)
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15 (55.6)
14 (35.0)
8 (12.9)
18 (35.3)
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35 (34.7)
54 (45.8)
93 (6.0)
275 (12.5)
2 (1.2)
4 (0.6)
2 (0.0)
5 (1.6)
6 (11.1)
3 (5.8)
7 (12.7)
8 (1.8)
16 (0.7)
12 (0.4)
23 (2.7)
20 (0.6)
27 (1.9)
29 (2.4)
36 (0.9)
38 (3.1)
38 (6.1)
85 (2.0)
145 (1.6)
193 (1.9)
258 (13.9)
283 (9.8)
1240 (2.3)
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99% or 95% CI
0.2 0.5 1 2 5 10
Study
Statin better Control better
Odds ratio (CI) for
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Odds ratio (CI) for
statin v control
Statin
1 (4.5)
5 (25.0)
11 (45.8)
13 (40.6)
10 (40.0)
36 (90.0)
17 (27.4)
17 (33.3)
23 (33.3)
35 (35.0)
56 (56.6)
64 (55.2)
96 (6.2)
384 (17.4)
0 (0.0)
0 (0.0)
3 (0.1)
5 (1.5)
5 (9.3)
10 (18.5)
10 (18.2)
8 (1.9)
12 (0.6)
21 (0.6)
16 (1.9)
26 (0.8)
32 (2.3)
31 (2.5)
33 (0.8)
45 (3.8)
50 (7.9)
82 (1.9)
171 (1.9)
177 (1.7)
294 (16.0)
264 (9.1)
1295 (2.5)
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-4.5 (5.0)
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-6.7 (6.3)
-8.5 (9.8)
-11.0 (12.5)
-5.5 (14.7)
-1.2 (44.4)
-55.9 (114.1)
1.0 (0.5)
1.1 (0.8)
-0.5 (1.2)
0.1 (2.5)
0.5 (2.5)
-3.4 (2.9)
-1.5 (3.6)
0.0 (3.9)
2.0 (7.0)
-4.5 (8.2)
3.4 (9.5)
-3.0 (11.4)
-2.7 (14.4)
-0.9 (14.6)
1.9 (17.1)
-3.7 (20.0)
-5.4 (20.5)
0.8 (40.9)
-13.0 (77.6)
8.0 (90.8)
-19.5 (117.4)
10.5 (123.9)
-28.8 (591.4)
Observed −
expected
(variance)
Fig 2 |Effect of statin treatment on atrial fibrillation in 13 shorter and 22 longer term trials of statin v control (test for
difference: χ2=18.6, df=1, P<0.001)
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DISCUSSION
Despite previous suggestions, this meta-analysis of
published and unpublished information from larger
scale trials found no evidence for the use of statins in
the prevention of atrial fibrillation. During recent
years, statins have emerged as one of the most effec-
tive treatments to reduce the burden of cardiovascular
disease worldwide.61 Because of their remarkably
good safety profile and declining costs, there has
been some interest in the potential use of statins
as direct anti-arrhythmic or anti-inflammatory
drugs.12 62 Various hypothetical mechanisms for such
effects, mostly unrelated to their effects on low density
lipoprotein particles (though still possibly dose
related), have been proposed. The suggestion that
such “pleiotropic effects” reduce atrial fibrillation by
asmuch as one third, however, is not supported by our
meta-analysis.
Interpretation of apparently contradictory findings
While several methodological and clinical differences
between the shorter term and longer term trials pre-
clude a meaningful combination of the results, they
could help us understand the discrepant findings.
Table 2 | Summary of characteristics of longer term (with at least six months’ follow-up) hypothesis testing trials: statin versus control regimen
Study
Mean
follow-up
(years)
Country/
region Intervention/control Main inclusion criteria
Event capturing
methods
No in
intervention/
control
Mean
age
(years)
Male
(%)
Previous
MI (%)
Potential
risk of
bias
WOSCOPS,
199532
4.8 UK Pravastatin
40 mg/placebo
Primary prevention Periodic ECG
recording
3302/3293 55 100 0 Low
AFCAPS/
TexCAPS, 199833
5.3 USA Lovastatin
20-40 mg/placebo
Primary prevention Unpublished AE
reports
3304/3301 58 85 0 Low
GISSI-P, 200034 1.9 Italy Pravastatin
20 mg/no treatment
Recent MI Unpublished AE
reports
2138/2133 60 86 100 Low
ALLHAT-LLT,
200235
4.8 North
America
Pravastatin
40 mg/usual care
Hypertension plus other
risk factor
Periodic ECG
recording
4327/4255 66 51 0 Low
HPS, 200236 5.0 UK Simvastatin
40 mg/placebo
Vascular disease or
diabetes
Unpublished AE
reports
10 269/10 267 64 75 41 Low
LIPS, 200237 3.1 Europe,
Canada,
Brazil
Fluvastatin
80 mg/placebo
Post PCI Unpublished AE
reports
844/833 60 84 44 Low
PROSPER, 200238 3.2 Scotland,
Ireland,
Netherlands
Pravastatin
40 mg/placebo
Elderly with vascular
disease or high risk
Periodic ECG
recording,
unpublished
2891/2913 75 48 13 Low
ASCOT-LLA,
200339
3.2 Nordics, UK,
Ireland
Atorvastatin
10 mg/placebo
Hypertension plus other
risk factors
Unpublished AE
reports
5168/5137 65 81 0 Low
ALLIANCE, 200440 4.3 USA Atorvastatin
10-80 mg/usual care
CHD Unpublished AE
reports
1217/1225 61 82 58 Low
CARDS, 200441 3.9 UK, Ireland Atorvastatin
10 mg/placebo
Type 2 diabetes plus other
risk factor
Unpublished AE
reports
1428/1410 62 68 0 Low
PREVEND IT,
200442
3.8 Netherlands Pravastatin
40 mg/placebo
Microalbuminuric patients Unpublished AE
reports
433/431 51 65 0 Low
PCAB, 200543 4.5 Japan Pravastatin
10-20 mg/usual care
After CABG Unpublished AE
reports
168/167 59 85 62 Low
4D, 200544 3.9 Germany Atorvastatin
20 mg/placebo
Haemodialysis patients
with diabetes
Unpublished AE
reports
619/636 66 54 18 low
MEGA, 200645 5.3 Japan Pravastatin
10-20 mg/no
treatment
Primary prevention Unpublished AE
reports
3866/3966 58 32 0 Low
ASPEN, 200646 4.3 Multinational Atorvastatin
10 mg/placebo
Type 2 diabetes Unpublished AE
reports
1211/1199 61 66 16 Low
Sola, 200647 1.0 USA Atorvastatin
20 mg/placebo
Non-ischaemic CHF Unpublished AE
reports
54/54 54 34 0 Low
GISSI-HF, 200848 3.9 Italy Rosuvastatin
10 mg/placebo
CHF Serial ECG recording
and AE reports
1855/1835 68 77 32 Low
ATAHEB, 200849 1.0 Taiwan Atorvastatin
20 mg/usual care
Pacemaker for
bradyarrhythmias
Pacemaker
interrogation
52/54 71 45 0 High
Vrtovec et al,
200850
1.0 Slovenia Atorvastatin
10 mg/usual care
CHF Unpublished AE
reports
55/55 63 61 59 Low
METEOR, 200851 2.0 Multinational Rosuvastatin
40 mg/placebo
Low risk for cardiovascular
event
Unpublished AE
reports
702/282 57 60 0 Low
JUPITER, 200852 1.8 Multinational Rosuvastatin
20 mg/placebo
Primary prevention Unpublished AE
reports
8901/8901 66 62 0 Low
LEADe, 201053 1.5 Multinational Atorvastatin
80 mg/placebo
Mild to moderate probable
Alzheimer’s disease
Unpublished AE
reports
314/326 74 48 0 Low
ECG: electrocardiography; AE=adverse event; MI=myocardial infarction; CHD=coronary heart disease; CABG=coronary artery bypass graft surgery; CHF=chronic heart failure; PCI=percutaneous
coronary intervention.
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Firstly, the two sets of trials differed in methods of
detection and verification of the outcome. The shorter
term trials generally used more sensitive methods for
event capturing than the longer term trials. For exam-
ple, brief asymptomatic periods of atrial fibrillation
that were detected on continuous cardiac monitoring
were classified as events in some shorter term studies.
In contrast, events in many of the longer term studies
were based on clinical reports collected from adverse
event forms that are more likely to be relevant to
patients. In most longer term trials, atrial fibrillation
was not a prespecified end point, and this might have
resulted in underestimation of the true number of
events and hence larger random errors in those parti-
cular studies.63 Such passive collection of event infor-
mation is unlikely to have introduced any bias because
under-reporting would be likely to occur similarly in
each treatment group. The events in the longer term
trials were also not generally adjudicated, but even
when the analysis was restricted to those seven trials
of statin versus control that had independently con-
firmed the events,32 35 38 41 42 48 49 there was no suggestion
of a reduction in the risk of atrial fibrillation, indicating
that lack of complete event adjudication is unlikely to
have had a major impact on the results.
Secondly, the absolute risk of atrial fibrillation and
the clinical condition of the patients included in the two
sets of trials were quite different. Notwithstanding the
differences in methods of event capturing used
between the trials, the average underlying absolute
risk of atrial fibrillation was higher in patients included
in the shorter term trials than in those included in the
longer term trials because of differences in selection
criteria. While there is no a priori reason to suggest
that absolute risk should influence the relative effect
of treatment, it might sometimes help to explain
some of the heterogeneity observed if, for example, it
is associated with other biological or clinical factors
that influence treatment effects. In the context of atrial
fibrillation, future risk depends largely on the degree of
atrial structural alterations (that is, atrial
remodelling).64 If anything, drugs that are effective
for the treatment of atrial fibrillation in people at low
risk with a structurally normal heart might be expected
Table 3 | Summary of characteristics of longer term (with at least six months’ follow-up) hypothesis testing trials: more intensive versus less intensive statin
treatment
Study
Mean
follow-up
(years)
Country/
region Intervention/control Main inclusion criteria
Event capturing
methods
No in
intervention/
control
Mean
age
(years)
Male
(%)
Previous
MI (%)
Potential
risk of
bias
A-Z, 200454 2.0 Multinational Simvastatin
80 mg/20 mg
Acute coronary syndrome PublishedAEreports 2265/2232 61 76 17 Low
REVERSAL,
200413
1.5 USA Atorvastatin
80mg/pravastatin 40mg
>20% stenosis on routine
coronary angiogram
Unpublished AE
reports
328/329 56 72 0 Low
PROVE IT,
200454
2.0 Multinational Atorvastatin
80mg/pravastatin 40mg
Acute coronary syndrome PublishedAEreports 2099/2063 58 78 18 Low
TNT, 200555 4.9 Multinational Atorvastatin
80 mg/10 mg
Clinically evident CHD Unpublished AE
reports
4995/5006 61 81 58 Low
IDEAL,
200556
4.8 Nordics,
Netherlands,
Iceland
Atorvastatin 40-80 mg/
simvastatin 20-40 mg
Myocardial infarction Unpublished AE
reports
4439/4449 62 81 100 Low
Schmermund
et al, 200657
1 Germany Atorvastatin
80 mg/10 mg
No obstructive CHD Published AE report 235/234 61 75 0 low
Colivicchi et
al, 201058
0.7 Italy Atorvastatin
80 mg/20-40 mg
Acute presentation of
severe CHD
Unpublished AE
reports
144/146 75 48.6 100 Low
MI=myocardial infarction; AE=adverse event; CHD=coronary heart disease.
  Schmermund et al57
  REVERSAL13
  Colivicchi et al58
  A-Z54
  PROVE IT54
  TNT55
  IDEAL56
Total: 7 trials, P=0.99
Test for heterogeneity: χ2=12.7, df=6, P=0.05
2.04 (0.05 to 90.69)
0.67 (0.15 to 2.91)
0.50 (0.21 to 1.16)
1.56 (0.76 to 3.22)
0.88 (0.50 to 1.54)
0.90 (0.71 to 1.14)
1.12 (0.91 to 1.39)
1.00 (0.90 to 1.12)
2 (0.9)
6 (1.8)
18 (12.5)
35 (1.5)
44 (2.1)
248 (5.0)
357 (8.0)
710 (4.9)
0.1
99% or 95% CI
0.2 0.5 1 2 5 10
Study
Statin better Control better
Odds ratio (CI) for
statin v control
Odds ratio (CI) for
statin v control
Statin
1 (0.4)
9 (2.7)
33 (22.6)
22 (1.0)
49 (2.4)
274 (5.5)
321 (7.2)
709 (4.9)
Control
No of events (%)
0.5 (0.7)
-1.5 (3.7)
-7.3 (10.5)
6.3 (14.1)
-2.9 (22.7)
-12.7 (123.7)
18.4 (156.6)
0.7 (332.1)
Observed −
expected
(variance)
Fig 3 | Effect of statin treatment on atrial fibrillation in seven longer term trials of more intensive v standard statin regimens
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to have less effect in those with structural abnormal-
ities, as pre-existing atrial remodelling might be irre-
versible or less amenable to preventive medical
treatment.65 We found no evidence that statins pre-
vented atrial fibrillation in people with no history of
heart disease, and there was no significant evidence of
heterogeneity between trials that studied people at dif-
ferent underlying risk (fig 4). With the exception of the
MIRACL trial, 20 all the shorter term trials selected
either patients undergoing cardiac surgery, or electri-
cal cardioversion, or patients with a history of atrial
fibrillation.While it is unlikely that any potential pleio-
tropic effect of statins would be confined to these parti-
cular groups, there could be some other intermediary
mechanisms that could, at least in part, account for the
observed effect of statins in such settings. For example,
myocardial damage is commonly encountered after
coronary procedures66 and is a potential risk factor
for atrial fibrillation. 67 Therefore, a reduction in atrial
fibrillationmight result from just a short course of statin
treatment if this abrogatesmyocardial tissue injury.27 68
In contrast with those undergoing cardiac surgery,
however, the attributable risk for atrial fibrillation
from coronary events in less selected populations of
patients, such as those included in the longer term stu-
dies, is likely to be small. Thus, in the longer term stu-
dies any beneficial effects mediated through
prevention of myocardial injury would be likely to be
diluted by the much larger number of events that are
unrelated to acute myocardial injury.
Thirdly, differences in selection criteria between the
trials meant that the proportion of people with recur-
rences of known atrial fibrillation was much larger in
the shorter term trials than in the longer term trials. The
therapeutic goals in people with paroxysmal or persis-
tent atrial fibrillation might differ from those with no
known history of atrial fibrillation, as treatment in the
former group is usually expected only to delay the next
episode of atrial fibrillation or the transition to a per-
manent state. Although any such delaysmight be clini-
cally valuable, in meta-analyses of longer term studies
when information about timing of the events is not
available, delays in recurrences are likely to be missed
if a large proportion of individuals have experienced a
recurrence by the end of the study. This might also
obscure any beneficial effects on prevention of first
diagnosed atrial fibrillation if recurrences of atrial
fibrillation constitute a large proportion of total events.
In the current analyses, however, we found no evi-
dence that statins significantly reduced atrial fibrilla-
tion in the trials in which events were known to have
been first diagnosed events (fig 4). Furthermore, a pat-
tern of early separationwith a later convergence of risk
curves was not reported in the longer term trials that
provided a time based analysis. 35 48
Fourthly, the differences between our findings and
those of the earlier meta-analyses could be due, at least
in part, to publication bias (that is, the tendency for trial
results to be more likely to be published if they have
strikingly positive results than if the results are negative
or null).69 Publication bias can, along with other
sources of bias, produce large apparent effects when
treatments are actually ineffective, particularly when
included studies are based on a limited number of
events (as such studies are particularly susceptible to
large random errors and hence much more likely
than larger studies to lead to exaggerated estimates of
treatment effect). Indeed, this point is perhapswell illu-
strated in the current context by the null findings of the
MIRACL trial,20 which, despite being the largest study
included in the earliermeta-analyses and despite being
presented at a major medical conference in 2004, has
Type of event*
  Known first diagnosed events
  Known recurrent events
  Unknown
Heterogeneity: χ2=0.1, df=2, P=0.97
Previous disease†
  No previous coronary heart disease
  Previous coronary heart disease
  Previous heart failure or renal disease
Trend: χ2=0.6, df=1, P=0.45
Heterogeneity between three categories: χ2=5.05, df=2, P=0.08
Total: 22 trials
0.95 (0.81 to 1.12)
0.93 (0.58 to 1.47)
0.96 (0.83 to 1.13)
0.95 (0.82 to 1.10)
1.12 (0.88 to 1.41)
0.84 (0.67 to 1.06)
0.95 (0.88 to 1.03)
574 (4.1)
102 (38.2)
564 (1.5)
668 (1.9)
263 (1.8)
309 (12.0)
1240 (2.3)
0.599% or 95% CI 0.75 1 1.5 2
Study
Statin better Control better
Odds ratio (CI) for
statin v control
Odds ratio (CI) for
statin v control
Statin
597 (4.3)
114 (40.0)
584 (1.5)
700 (2.0)
236 (1.6)
359 (13.9)
1295 (2.5)
Control
No of events (%)
-13.3 (269.3)
-2.5 (32.9)
-10.0 (279.7)
-16.3 (325)
13.4 (122.5)
-22.9 (134.5)
-28.8 (591.4)
Observed −
expected
(variance)
Fig 4 | Effect of statin treatment on atrial fibrillation in 22 longer term trials of statin v control, by subgroups of trial population.
*Six trials could confirm that reported atrial fibrillation events were new (that is, incident) cases,323538414249 and one trial48
provided atrial fibrillation events in both those with and without history of paroxysmal atrial fibrillation at baseline. †No
previous coronary heart disease3233353839414245464951-53; previous coronary heart disease3436374043; previous heart failure or renal
disease44474850
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not to our knowledge yet been published as a full
report. In addition, the impact of the results fromMIR-
ACLon the overall estimates in the two previousmeta-
analyses9 10 was reduced because of the use of “random
effect” approaches.
In the presence of heterogeneity, “random effect”
approaches (which estimate the heterogeneity in treat-
ment effects across trials and incorporate this variabil-
ity into the estimate of the overall result) are commonly
used. In certain circumstances, however, such
approaches can lead to small potentially seriously
biased studies gaining an inappropriately large statisti-
cal weight at the expense of larger more reliable
studies.70 In contrast, we calculated our summary effect
estimates by taking a simple weighted average of the
like-with-like comparisons within each trial.While this
method is often referred to as being a “fixed effect”
method, the terminology is unsatisfactory because it
misleadingly suggests that any heterogeneity between
the true effects of treatment in different trials is
assumed to be zero (whereas no such unjustified
assumptions are involved). However, for comparison,
when we applied a standard random effect to themeta-
analysis of the 13 shorter term trials, the overall event
rate ratio was 0.47 (0.30 to 0.72; P<0.001) and the dif-
ference between the overall results from the shorter
and longer term studies remained significant
(P<0.001).
Strength and limitations
Ourmeta-analysis sought to obtain both published and
unpublished information from all eligible trials, and
the large number of events this provided gave good
statistical power to detect even modest treatment
effects.Wemight still havemissed relevant event infor-
mation from at least nine further trials. It is unlikely
that these data would have resulted in any material
change to our primary conclusions, however, because
they would have been expected only to have increased
the total number of person years, and hence statistical
information (that is, events), by about 10%. In addition,
if an important reduction in atrial fibrillation had been
observed in any single trial for which data were not
made available to us, it seems likely that that result
would have been published (as most of these trials
were completed several years ago) and would hence
have been identified by our literature search.
Conclusions and implications for clinicians and future
researchers
In contrast with the unequivocal evidence for the ben-
eficial effect of statins on atherosclerotic events in a
wide range of people, there is currently no compelling
evidence that longer term treatment with statins pre-
vents atrial fibrillation. While our study does not
exclude a real reduction in risk of about 10%, it casts
doubt over the existence of any sustained and clinically
relevant beneficial effect of statins for the prevention of
atrial fibrillation. The effect of statins on atrial fibrilla-
tion in particular populations of patients with selection
of outcomes that are relevant to patients andhealthcare
providers71 could be explored in future well designed
randomised trials.
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